Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation

Sponsor
I.R.C.C.S. Fondazione Santa Lucia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04691102
Collaborator
(none)
120
1
17
7.1

Study Details

Study Description

Brief Summary

Postural and balance disorders are common in neurological disorders. They are often associated with reduced mobility and fear of falling, which strongly limit independent activities of daily living (ADL), compromise the quality of life and reduce social participation. Here the investigators apply an existing software solution to: 1) obtain biomarkers of gait deficits in 5 neurological conditions, 2) develop an automatic procedure supporting clinicians in the early identification of patients at high risk of falling as to tailor rehabilitation treatment; 3) longitudinally assess these patients to test the efficacy of rehabilitation. High-density electroencephalography (EEG), and inertial sensors located at lower limbs and at upper body levels will be used to extract the most appropriate indexes during motor tasks. The ultimate goal is to develop cost-effective treatment procedures to prevent recurrent falls and fall-related injuries and favour the reintegration of the patient into everyday activities. The first hypothesis of this study is that clinical professionals (e.g., medical doctors and rehabilitative staff) would strongly benefit from the possibility to rely on quantitative, reliable and reproducible information about patients motor deficits. This piece of information can be nowadays readily available through miniaturized wearable technology and its information content can be effectively conveyed thanks to ad hoc software solution, like the A.r.i.s.e. software. The second hypothesis of the present study is that early identification of patients at high risk of dependence and the subsequent application of personalized treatment would allow for cost-effective treatment procedures to favor the autonomy into everyday activities. The results of this project could represent a valuable support in the clinical reasoning and decision-making process.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Dynamic Postural Stability Assessment in Neurorehabilitation
    Actual Study Start Date :
    May 1, 2021
    Anticipated Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Oct 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Stroke group

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Traumatic Brain Injury group

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Mild Cognitive Impairment group

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Parkinson Disease group

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Multiple Sclerosis group

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Healthy subjects groups

    Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times. The whole assessment procedure will last approximately 40 minutes.

    Outcome Measures

    Primary Outcome Measures

    1. Inertial sensors-based assessment [Baseline]

      Set of seven magneto-inertial sensors (Opal, APDM Inc., Portland, Oregon, USA). Gait quality indices related to dynamic stability, symmetry and smoothness will be extracted from the sensors' signals after the execution of a 10-Meter-Walk (10MWT), Figure-of-8-Walk (F8WT), and Fukuda-Stepping test (FST)

    Secondary Outcome Measures

    1. Berg Balance Scale (BBS) [Baseline]

      The Berg Balance Scale (BBS) is a 14-item objective measure that assess static balance and fall risk. The BBS values ranging from 0 to 56, where 0 means the worse outcome and the 56 the best one.

    2. Dynamic Gait Index (DGI) [Baseline]

      The Dynamic Gait Index (DGI) allows to assess the dynamic stability during march. The DGI values ranging from 0 to 24, where 0 means the worse outcome and 24 the best one.

    3. Balance Evaluation System Test (Mini-BESTest) [Baseline]

      The Balance Evaluation System Test (Mini-BESTest) allows to assess the dynamic balance. It is a 14-item test scored on 3-level ordinal scale. The Mini-BESTest values ranging from 0 to 28, where 0 means the worse outcome and 28 the best one

    4. Electroencephalography (EEG) [Baseline]

      A portable and low-weight 128-EEG channels system will be use in order to obtain neural predictors of gain stability during walking in the real-world and to distinguish types of walking. Briefly, source-space EEG signals (based on the individual anatomical image) will be reconstruct to estimate activity (e.g., power spectrum density-PSD) and connectivity (via FC correlation) at rest and during motor tasks

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 85 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria Stroke patients:
    • < 6 months from the acute event;

    • age range 18-85 years;

    • Functional Ambulation Category (FAC) ≥ 3.

    Exclusion Criteria Stroke patients:
    • Cognitive deficits (Mini Mental State Examination (MMSE) > 24);

    • Severe unilateral spatial neglect (diagnosed with Letter Cancellation test, the Barrage test, the Sentence Reading test and the Wundt-Jastrow Area Illusion Test);

    • Severe aphasia (diagnosed with neuropsychological assessment);

    • Neurological/orthopedic/cardiac comorbidities (clinically evaluated);

    • Alcohol or substance abuse.

    Inclusion Criteria Traumatic Brain Injury (TBI) patients:
    • Glasgow Coma Scale (GCS) ≤ 8;

    • Age range 15-65years;

    • Level of Cognitive Functioning (LCF): ≥ 7;

    • Adequate linguistic abilities; dynamic balance disorders;

    • Functional Ambulation Category (FAC)≥ 3; Exclusion Criteria Traumatic Brain Injury (TBI) patients

    • Glasgow Coma Scale (GCS) > 8;

    • Level of Cognitive Functioning (LCF) < 7;

    • Severe aphasia (based on neuropsychological assessment);

    • Absence of balance disorders;

    • Functional Ambulation Category (FAC) < 3

    • Alcohol or substance abuse.

    Inclusion Criteria Mild Cognitive Impairment (MCI) patients:
    • Age ≥ 60 Years

    • Normal Neurologic Examination

    • Cognitive decline reporting by the patient himself or by the caregiver.

    • Mini Mental State Examination (MMSE) score range: 23.88 ≤ MMSE ≤ 26 ( or ≤ 28 if the patient's schooling is up than 16 years.

    • Functional Independence

    • Clinical Dementia Rating (CDR) <1.

    Exclusion Criteria Mild Cognitive Impairment (MCI) patients:
    • Presence of overt dementia

    • Other clinical and/or neurological condition which could compromise the assessment.

    • Alcohol or substance abuse

    Inclusion Criteria Parkinson Disease patients (PD):
    • Absence of dementia (Mini-Mental State Examination score (MMSE)> 25);

    • Age range 40-80 years;

    • Hoehn & Yahr 2-3;

    • Walking autonomy

    Exclusion Criteria Parkinson Disease patients (PD):
    • Dementia (Hoehn & Yahr) > 3;

    • Severe cardiological / pulmonary / orthopaedic / metabolic conditions that prevent the trial participation;

    Inclusion Criteria Multiple Sclerosis (MS) patients:
    • Age range 30-65 years

    • Diagnosis of Multiple Sclerosis (MS) according with revisited McDonalds criteria;

    • Expanded Disability Status Scale (EDSS) ranging between 0 and 6;

    • Ability to walk independently or with aid for at least 50 meters.

    Exclusion Criteria Multiple Sclerosis (MS) patients:
    • Associated psychiatric and/or neurological disorders (different from the MS);

    • Clinical relapse within the three months prior to enrollment;

    • Steroid therapy within 30 days before the enrollment;

    • Peripheric diseases as visual and/or auditory impairments that could interfere with motor and cognitive tasks execution;

    • Fracture of lower limb within three months before the enrollment.

    Inclusion Criteria Healthy subjects:
    • Age range 18-80 years
    Exclusion Criteria Healthy subjects:
    • Any neurological/orthopedic/cardiac condition (clinically evaluated)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Santa Lucia Foundation I.R.C.C.S. Roma Rm Italy 00179

    Sponsors and Collaborators

    • I.R.C.C.S. Fondazione Santa Lucia

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Marco Tramontano, Head of Rehabilitation Services, I.R.C.C.S. Fondazione Santa Lucia
    ClinicalTrials.gov Identifier:
    NCT04691102
    Other Study ID Numbers:
    • Prot. CE/PROG.877
    First Posted:
    Dec 31, 2020
    Last Update Posted:
    Mar 17, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 17, 2022